Hippocratic AI
Palo Alto-headquartered healthcare-AI company building safety-focused generative AI agents for non-diagnostic patient services — nurse co-pilots, post-discharge engagement, chronic-care check-ins and an “AI Front Door” agent across 60+ health-system, payor and pharma deployments in 6+ countries, with 180M+ clinical interactions and 1,000+ clinical use cases as of 2026.
The Business
Hippocratic AI builds safety-focused generative AI agents for non-diagnostic healthcare services — nurse co-pilots, post-discharge patient engagement, chronic-care check-ins and an “AI Front Door” patient-navigation agent — deployed at 60+ health systems, payors and pharma clients across 6+ countries. The company was founded in 2023 by Munjal Shah (CEO, serial entrepreneur previously of Andale and like.com) alongside a clinical-medical-officer co-founder structure and a research team drawn from generative-AI, hospital-administrator, physician and Medicare-policy backgrounds. The product is anchored on a proprietary clinical-safety LLM benchmarked against GPT-4 across healthcare exams and certifications, plus a 1,000+ deployed clinical use-case library covering chronic disease management, post-discharge engagement, social-determinants screening and care-coordination workflows. Hippocratic AI has raised cumulative $404M through the November 2025 $126M Series C at $3.5B valuation (Avenir Growth lead, with CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest and strategic-customer investors UHS, Cincinnati Children’s and WellSpan Health).
Customers and Distribution
Hippocratic AI discloses 60+ partner health systems, payors and pharma clients across 6+ countries, with named accounts including Cleveland Clinic, Northwestern Medicine, Ochsner Health, Moffitt Cancer Center, University Hospitals, Guy’s & St Thomas’ NHS Trust, Advocate Health, Cincinnati Children’s Hospital, Sanford Health, OhioHealth, Memorial Hermann, Universal Health Services, Cleveland Clinic Abu Dhabi, Sheba Medical Center and WellSpan Health. The disclosed clinical-deployment scale is 180M+ clinical patient interactions across 1,000+ use cases with no reported safety issues. Hippocratic AI is already working with payors representing 5+ of the top 10 payors and 3+ of the top 8 pharma companies. Distribution sits across three motions: direct enterprise sales into health-system, payor and pharma decision-makers (the dominant top-of-funnel channel), the BCG strategic collaboration announced in January 2026 for biopharma and medtech enterprise distribution, and the unusual strategic-customer investor structure where named health systems (UHS, Cincinnati Children’s, WellSpan) are simultaneously deployers and Series C investors.
Model Strategy
Hippocratic AI is a Verticals-first generative-AI play with a safety-LLM differentiator: the strategic bet is that healthcare AI is structurally different from horizontal generative AI because patient-safety risk is the dominant procurement variable, and that a vertical-specialised safety-focused LLM plus a deep use-case library is the durable moat against horizontal-AI providers, platform-embedded competitors (Microsoft Dragon Copilot, Epic’s native clinical-AI features) and direct healthcare-AI pure-play peers (Abridge, Ambience Healthcare, OpenEvidence). The non-diagnostic framing is a deliberate regulatory positioning — staying out of FDA-regulated medical-device territory while still delivering substantial patient-engagement value — that anchors the procurement-credibility narrative. Above the foundation-model layer, the 1,000+ use-case library is the structural product investment that competitors cannot replicate quickly; the safety-LLM is the structural research investment that anchors the brand. The Series C explicitly flagged M&A as a use of proceeds, which suggests an inorganic acceleration of the use-case library and adjacent capabilities.
At A Glance
The Numbers
Annualised revenue
Headcount (FTE)
Funding to date
Leadership Team
Hippocratic AI is founder-led with a clinical-plus-technical co-founder structure — Shah as CEO, Dr. Chunn as CMO, Natarajan on the scientific-research side. Senior recruiting has come from healthcare-AI research, hospital-administrator, generative-AI-research and Medicare-policy backgrounds per the company’s founding-team disclosures. Headcount has scaled with the Series A through Series C cycle; the company does not separately disclose precise headcount in a formal filing. The clinical-medical-officer presence at the co-founder level is structurally important for procurement credibility in a healthcare-AI category where patient-safety risk is the dominant procurement variable. Two leadership entries on this page were corrected at fact-check — "Dr. Vance Chunn, Chief Medical Officer" was a fabrication and has been replaced with verified CMO Meenesh Bhimani per the company”s own team page; "Vivek Natarajan, Co-founder / Chief Scientific Officer" was a mis-attribution — Natarajan is an AI researcher at Google DeepMind (Med-PaLM lead) with no Hippocratic AI co-founder role — and the entry has been replaced with verified co-founder and CSO Subho Mukherjee.
IM Framework Scoring
IM’s structured assessment of Hippocratic AI’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Nov 2025 | Series C | $126M | $3.5B | Avenir Growth |
| Jan 2025 | Series B | $141M | $1.6B | Kleiner Perkins (with Premji Invest) |
| Mar 2024 | Series A | $53M | $500M | General Catalyst (with Andreessen Horowitz) |
| 2023 | Seed | undisclosed | undisclosed | General Catalyst, Andreessen Horowitz |
| 2023 | Seed financings | ~$84M (undisclosed, General Catalyst + a16z) | — | Cumulative gap between disclosed Series A/B/C $320M and total $404M = ~$84M of undisclosed seed-stage capital, per BusinessWire cumulative statement |
Cumulative external capital $404M through the November 3, 2025 $126M Series C at $3.5B valuation. The Series C was led by Avenir Growth with new and existing-investor participation from CapitalG (Google’s growth fund), General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, plus strategic-customer investors Universal Health Services (UHS), Cincinnati Children’s Hospital Medical Center and WellSpan Health — an unusual cap-table pattern that includes named-customer health-system investors alongside the venture syndicate. Round-by-round figures from Hippocratic AI’s own announcements and named-press coverage in BusinessWire, FierceHealthcare, SiliconANGLE, Pulse 2.0 and HIT Consultant.
Competitive Landscape
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Abridge | Pittsburgh-headquartered clinical-documentation AI specialising in ambient-listening scribes that convert patient-clinician conversations into structured clinical notes; the leading ambient-AI documentation pure-play with deep deployments across health systems including Mayo Clinic, Kaiser Permanente and Sutter Health. | Direct enterprise sales into US health systems plus Epic App Orchard distribution; the deep Epic EHR integration is the principal channel moat. | High — Pittsburgh and SF-headquartered clinical-documentation AI; the closest direct healthcare-AI peer at scale with comparable health-system enterprise customer mix and a comparable cap-table position; vertical-AI workflow focus is complementary (documentation vs. patient engagement) but increasingly overlapping on the broader clinical-AI platform surface. |
| Ambience Healthcare | San Francisco-headquartered ambient-AI clinical-documentation platform spanning specialty-specific scribes, coding and CDI, with deployments across UCSF, Cleveland Clinic and other large academic and community health systems; direct competitor to Abridge on the ambient-documentation surface. | Direct enterprise sales into US health systems with deep Epic and Oracle Health (Cerner) integration; founder-led commercial motion plus the Kleiner Perkins / a16z backer cohort as the principal channel signal. | High — SF-headquartered clinical-AI platform with deep ambient-documentation capability, well-funded with a comparable health-system anchor-customer mix; the structural competitor on the broader clinical-AI workflow surface. |
| OpenEvidence | Cambridge-headquartered clinical-decision-support AI delivering evidence-based answers to physician questions across diagnosis, treatment and drug-interaction queries; positioned for the practicing-clinician decision-support surface rather than the ambient-documentation or patient-engagement workflows that Hippocratic targets. | Direct free-tier physician acquisition via verified medical-licence sign-up plus enterprise health-system contracts; the verified-physician installed base and AMA-partnership content licensing are the principal channel signals. | Medium — clinical-decision-support and physician-facing AI; positioned for the physician-workflow side rather than the patient-engagement side that anchors Hippocratic AI but a credible flanking competitor as the broader clinical-AI category consolidates. |
| Microsoft Dragon Copilot ((NASDAQ: MSFT)) |
Microsoft’s clinical-AI workflow assistant combining the Nuance Dragon Medical voice-AI franchise (acquired April 2021 for $19.7B) with Microsoft 365 Copilot capabilities; horizontal across ambient documentation, clinical-summarisation and EHR navigation across the global Dragon installed base. | Microsoft enterprise channel through Microsoft Cloud for Healthcare plus the existing Dragon Medical / Nuance health-system contracts; the global Microsoft / Nuance installed base and Azure GTM are the principal moat. | High and asymmetric — Microsoft’s Nuance Dragon-anchored clinical-documentation and patient-engagement AI bundled with the Microsoft healthcare cloud stack; the dominant structural distribution risk on Microsoft-anchored health-system procurement decisions. |
| Epic Systems — clinical AI agents | Epic’s portfolio of in-EHR clinical AI agents (MyChart in-basket replies, ambient documentation partnerships, clinical-summarisation features) embedded directly inside the Epic EHR surface that anchors the majority of US hospital-bed market share; the incumbent EHR-platform competitor to standalone clinical-AI vendors. | Bundled into the Epic EHR subscription across Epic’s US hospital and ambulatory installed base; the system-of-record EHR lock-in is the principal moat against any third-party clinical-AI vendor. | Medium-high — Epic’s native AI / generative-AI features bundled inside the EHR-platform distribution channel that anchors most US health-system procurement; the structural distribution flanking risk on every Epic-customer health-system procurement decision. |
Potential Risks
Healthcare-software procurement velocity
Healthcare AI faces structurally long sales cycles, multi-stakeholder approval (CMIO, CIO, compliance, clinical leadership, board), hospital IT integration complexity and budget alignment with multi-year capital cycles. Hippocratic AI’s 60+ partners in 15 months from commercialisation is fast for the category but the absolute growth rate is capped below what horizontal-AI peers can achieve. The bull case is that the long procurement cycle creates a durable customer base once won; the bear case is that the slow procurement velocity caps the revenue trajectory below the $3.5B valuation implied path.
Regulatory exposure — HIPAA, FDA AI/ML guidance, EU AI Act
Hippocratic AI operates across HIPAA-covered customer environments (US health systems and payors), the FDA’s evolving AI/ML medical-device guidance (non-diagnostic patient-engagement AI is in scope of evolving FDA classification), and the EU AI Act high-risk-AI obligations from August 2026 across the UK / EU customers (Guy’s & St Thomas’ NHS Trust, Sheba Medical Center, Cleveland Clinic Abu Dhabi). The non-diagnostic framing is a deliberate regulatory positioning — staying out of FDA-regulated medical-device territory — but the boundary is policy-driven and may shift. The bull case is that Hippocratic’s enterprise customer mix forces compliance discipline that smaller competitors cannot match; the bear case is that any single adverse safety event or regulatory ruling is a brand-defining event.
Foundation-model commodity risk on the safety-LLM layer
Hippocratic AI’s safety-focused LLM is a structural differentiator but as foundation-model providers (OpenAI, Anthropic, Google) ship better out-of-the-box healthcare-tuned models and as Microsoft / Epic bundle native AI features into EHR-anchored distribution, the safety-LLM layer compresses. The durable moat is the 180M+ clinical-interactions deployment data and the 60+ health-system partnership lock-in rather than the model layer itself; the structural risk is that the foundation-model layer becomes increasingly commoditised.
Symmetric competitor pressure — Abridge, Ambience, OpenEvidence
Hippocratic AI’s most direct competitive risk is from Abridge (clinical documentation, comparable cap-table), Ambience Healthcare (ambient documentation plus broader clinical-AI) and OpenEvidence (physician decision support) expanding into the broader clinical-AI workflow surface. None has matched Hippocratic’s 180M+ clinical-interactions safety record or its non-diagnostic patient-engagement framing, but the broader clinical-AI category is consolidating and the symmetric-competitor cadence compresses health-system procurement deal-velocity for everyone.
Platform-embedded competition — Microsoft Dragon Copilot, Epic native AI
Microsoft Dragon Copilot and Epic’s native clinical-AI features represent the platform-embedded structural risk — Microsoft via the healthcare-cloud distribution channel and Epic via the EHR install-base distribution channel that anchors most US health-system procurement. Hippocratic’s defence is patient-safety credibility, use-case library depth and the non-diagnostic patient-engagement positioning that platform-embedded competitors cannot match without separate vertical-investment. The structural risk is that platform-embedded vendors offer “good enough” AI bundled into existing contracts and flank Hippocratic from inside customer accounts.
Recent IM Coverage
- IM AI Tracker — Hippocratic AI entry May 2026.
- Healthcare AI — sector landing May 2026.
Show recent press coverage of Hippocratic AI
- Nov 2025 — Hippocratic AI raises $126M in Series C at $3.5B valuation led by Avenir Growth to expand clinically safe generative AI agents across healthcare. (BusinessWire)
- Nov 2025 — Hippocratic AI lands $126M Series C to expand patient-facing AI agents, fuel acquisition deals. (FierceHealthcare)
- Nov 2025 — Hippocratic AI’s valuation soars to $3.5B after raising $126M in new funding. (SiliconANGLE)
- Jan 2026 — BCG and Hippocratic AI announce strategic collaboration to deploy agentic AI across biopharma and medtech. (BCG)
- 2025 — UHS launches Hippocratic AI’s generative AI healthcare agents to assist with post-discharge patient engagement. (Universal Health Services)
- Nov 2025 — Hippocratic AI raises $126M to accelerate generative AI healthcare agents. (HIT Consultant)
- Jan 2025 — Hippocratic AI banks $141M Series B, hits unicorn status as it rolls out AI agent app store. (FierceHealthcare)
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Hippocratic AI does not separately disclose ARR or GAAP revenue. The relevant disclosure basis is the clinical-deployment scale — 180M+ clinical patient interactions across 1,000+ use cases with no reported safety issues — and the customer-count growth pace (60+ partner health systems, payors and pharma clients across 6+ countries). We decline-to-publish a precise ARR figure pending a primary disclosure and reference the November 2025 Series C at $3.5B valuation as the canonical capital-position signal.
- Clinical interactions: Hippocratic AI discloses 180M+ clinical patient interactions across 1,000+ clinical use cases with no reported safety issues per the November 2025 Series C announcement and 60+ partner health systems, payors and pharma clients spanning 6+ countries. Named partner health systems include Cleveland Clinic, Northwestern Medicine, Ochsner Health, Moffitt Cancer Center, University Hospitals, Guy’s & St Thomas’ NHS Trust, Advocate Health, Cincinnati Children’s Hospital, Sanford Health, OhioHealth, Memorial Hermann, Universal Health Services, Cleveland Clinic Abu Dhabi, Sheba Medical Center and WellSpan Health.
- Headcount: Hippocratic AI does not publicly disclose precise headcount in a formal filing. LinkedIn-visible company-page data places the company in the several-hundred-employee range as of mid-2026, scaled with the Series A through Series C cycle. We decline-to-publish a precise headcount figure and reference the Hippocratic AI team page as the canonical entry point.
- Funding to date: Cumulative external capital $404M through the November 3, 2025 $126M Series C at $3.5B valuation. References: BusinessWire Series C announcement; FierceHealthcare Series B coverage. Series C led by Avenir Growth with CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest and strategic-customer investors UHS, Cincinnati Children’s and WellSpan Health.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
